GlassScriptPhysician profile
Silke Hoosier
NPI 1881133643
$2,305.27
in general payments reported to CMS, 2019-2025
17 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $670 · 2022: $376 · 2023: $565 · 2024: $483 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.00 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $323.09 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $207.27 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.05 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $131.04 | 2021-2024 | |
| Pfizer INC. | $107.42 | 2021-2025 | |
| Dexcom, INC. | $101.73 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $77.58 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $74.18 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $62.63 | 2021-2025 | Airsupra |
| Glaxosmithkline, LLC. | $55.37 | 2021-2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $53.89 | 2021 | |
| Exact Sciences Corporation | $48.74 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $43.11 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $41.02 | 2021-2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.92 | 2022 | |
| Axsome Therapeutics, INC. | $22.23 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silke Hoosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.